The content on this site is intended for healthcare professionals only
Dr John Heymach and Prof Richard Schilsky comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from a study looking at the use of PD-1 immunotherapy versus chemo alone as first line lung cancer treatment.
For more on these results, watch Dr Lopes present the data in the press conference, watch his interview with ecancer and read our news coverage here.
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Synthetic biology and precision medicine in blood and gynaecological cancers
Lung Cancer
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
OncoAlert Round Up for August 4th - 10th, 2023
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
